Mesothelioma is a rare and deadly form of cancer that has developed from exposure to asbestos. The inhalation of toxic asbestos is the major cause of mesothelioma. Captured particles of asbestos develop cancer or malignant cells in mesothelium. Mesothelium is the cell structure that covers and surrounds various internal organs. Mesothelioma develops the abnormal proliferation of malignant cells in organs such as heart, lung andStomach.
Mesothelioma is in three forms: pleural mesothelioma, peritoneal mesothelioma and pericardial mesothelioma classified. Pleura, the membrane structure, the lungs and lines the wall of the chest cavity cover. Most organs in the abdominal cavity through the peritoneum covered. Pericardial Mesothelioma is based on the cavity that encloses the heart.
Mesothelioma begin in tiny pieces in the membrane ofPleura. This can not be shown on scans or X-rays until they are very developed and cultivated. Mainly because people who have asbestos particles, which are considered the major cause of breathing developed for this disease. Symptoms can occur between 30 and 50 years after exposure to asbestos on the particles.
In the case of pleural mesothelioma are shortness of breath and chest pains from the fluid accumulated in the pleura as the mainSymptoms. Continuous cough and hoarseness are also identified other important symptoms in pleural mesothelioma. Abdominal pain, weight loss and abdominal swelling from fluid accumulation are the symptoms of peritoneal mesothelioma.
Symptoms such as intestinal obstruction, blood clotting abnormalities, fever and anemia are the symptoms of a pair of peritoneal dialysis. Pain, difficulty swallowing, or swelling of the neck or face is the most common symptom that is currentlythe cancer spreads beyond the mesothelium to other organs of the body. The symptoms of pericardial mesothelioma are persistent cough, palpitations and shortness of breath and chest pain. It 'very important to consult a doctor for further diagnosis immediately if you experience these symptoms.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น